Guides & Guidelines

Recommendations of International Society of Amyloidosis on the Management of Patients with Systemic Amyloidosis During the COVID-19 Pandemic
Patients with systemic amyloidosis should be considered at increased risk of complications and mortality in case of SARS-CoV2 infection. This may be particularly…
Read more
Management of Systemic AL Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein…
Read more
Subscribe to